/biz/ - Business & Finance

CURE is the answer. Face it, people get sick or grow old every day, the growth of this business is as inevitable as our own demise. The desire to live long, better and more fufilling lives is insatiable. From durable goods like devices, volume based income from patient flow to the more gossamer revenue streams generated from physician labor, the health care sector is extraordinarily diversified. No matter how long we live, how healthy we get or what advances science brings, people will always want to live longer and spend more time with their loved ones or friends on an anonymous Kyrgyzstani energy drink review board.

The need for health care is universal, it gives nary a shit for nation, creed, hue, gender, asshole tightness or any other such vanity. The multitude cries out, their plea, a better life. Their answer? The CURE, a 3X leveraged ETF which couples a single entry point with the the best companies that the sector has to offer, then pushes these already stellar returns to the limit with maximum leverage. With CURE, your economic interests are aligned with powerhouses such as UNH, MRK, PFE, ABT, BMY, MDT, UTHR, CVS, GILD, CI and from what I have been hearing in the rumor mill, soon TMDX. Real companies with innovative products that people don't simply want, but they need. Like all leveraged ETFs, CURE is rebalanced daily, deftly mitigating margin risks.

Since it's inception, CURE has provided a staggering 120% return but worry not, we're still early enough to get aboard the train. Health is synonymous with life, the growth of this sector will proceed exponentially until every viable space is saturated with it. This is a fait accompli; the sheer number of interested parties and compelling outcomes make it so. Where we're going, fretting over a few dollars is meaningless. The deliberation is over; waiting is a failure mode. Buy the CURE.